Cargando...
TIM-3, a promising target for cancer immunotherapy
Patients with malignant tumor treated with immunotherapy have received significant clinical benefits over the years. Immune checkpoint blocking agents, such as anti-cytotoxic T-lymphocyte-associated protein-4 (anti-CTLA-4) and anti-programmed cell death protein-1 (anti-PD-1) monoclonal antibodies, h...
Guardado en:
| Publicado en: | Onco Targets Ther |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6198883/ https://ncbi.nlm.nih.gov/pubmed/30410357 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S170385 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|